MV-CHIK

Themis Bioscience GmbH · Phase 2 active Biologic

At a glance

Generic name	MV-CHIK
Also known as	MV-CHIK vaccine, MV-CHIK/DP
Sponsor	Themis Bioscience GmbH
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) (PHASE2)
Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine (PHASE2)
Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) (PHASE2)
Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area (PHASE2)
Phase I Trial of Measles Vectored Chikungungya Vaccine (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MV-CHIK CI brief — competitive landscape report
MV-CHIK updates RSS · CI watch RSS
Themis Bioscience GmbH portfolio CI